Indomethacin Extended-Release Capsules USP 75 mg + Indomethacin Extended Release Capsules USP 75 mg
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout Indomethacin Extended-Release Capsules USP 75 mg + Indomethacin Extended Release Capsules USP 75 mg
Indomethacin Extended-Release Capsules USP 75 mg + Indomethacin Extended Release Capsules USP 75 mg is a phase 1 stage product being developed by Ipca Laboratories for Fed. The current trial status is completed. This product is registered under clinical trial identifier NCT01722110. Target conditions include Fed.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01722110 | Phase 1 | Completed |
Competing Products
20 competing products in Fed